Elevated resting heart rate in heart transplant recipients: innocent bystander or adverse prognostic indicator? UTAH (Utah Transplant Affiliated Hospitals)

Slides:



Advertisements
Similar presentations
© 2010, American Heart Association. All rights reserved. A Validated Risk Score for In-hospital Mortality in Patients with Heart Failure from the American.
Advertisements

Does Preoperative Hemoglobin Value Predict Postoperative Cardiovascular Complications after Total Joint Arthroplasty? Kishor Gandhi MD, MPH, Eugene Viscusi.
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2010.
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2012 J Heart Lung Transplant Oct; 31(10):
analysis from the SHIFT study
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Ultra long term outcomes in adult survivors of tetralogy of Fallot and the effect of pulmonary valve replacement Dobson R1,2, Danton M2, Walker N2, Tzemos,
Renal function and clinical outcomes of patients undergoing ICD and CRTD implantation- Data from the Israeli ICD Registry Alon Eisen, Mahmoud Souleiman,
Complete Recovery of Renal Function After Acute Kidney Injury is Associated with Long-Term All-Cause Mortality In a Large Managed Care Organization Jennifer.
INFLUENCE OF HLA MISMATCH ON GRAFT SURVIVAL IN RENAL TRASPLANTATION IN ADULTS IN ARGENTINA Bisigniano Liliana MD., López-Rivera Arturo MD., Tagliafichi.
HEART TRANSPLANTATION Pediatric Recipients JHLT Oct; 32(10):
Thomas S. Rector, PhD, Inder S. Anand, MD, David Nelson, PhD, Kristine Ensrud, MD and Ann Bangerter, MS CHF QUERI NETWORK November 8, 2007 VA Medical Center,
Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Red Cell Distribution Width (RDW) as a Novel Prognostic Marker in Heart Failure: Data from the CHARM Program and the Duke Databank.
Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction Robert O. Bonow, MD April 4, 2011 On behalf of the STICH Trial Investigators.
HEART-LUNG TRANSPLANTATION Adult Recipients JHLT Oct; 32(10):
HEART TRANSPLANTATION Pediatric Recipients 2014 JHLT Oct; 33(10):
Safety and Efficacy of Switching from Either UFH or Enoxaparin Plus a GP IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with Non-ST Elevation.
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
LUNG TRANSPLANTATION Adult Recipients 2014 JHLT Oct; 33(10):
Preoperative Hemoglobin A1c and the Occurrence of Atrial Fibrillation Following On-pump Coronary Artery Bypass surgery in Type-2 Diabetic Patients Akbar.
“SEVERE MENTAL ILLNESS & CONGESTIVE HEART FAILURE OUTCOMES AMONG VETERANS” by Jim Banta UCLA Committee members: Alexander Young, Gerald Kominksi, William.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
The CHART-2 Study (The Chronic Heart Failure Analysis and Registry in the Tohoku District 2) Source Shiba N, Nochioka K, Miura M, et al. Trend of westernization.
Is it possible to predict New Onset Diabetes After Transplantation (NODAT) in renal recipients using epidemiological data alone? Background NODAT is an.
Management of Hypertension according to JNC 7
Transitions in Care-Heart Failure
An analysis of 22,672 patients from the CLARIFY registry
- Higher SBP visit-to-visit variability (SBV) has been associated
2016 Annual Data Report, Vol 2, ESRD, Ch 6
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
History Of Atrial Fibrillation In A First-Degree Relative
Results from the intermountain heart collaborative study
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Validation of a Clinical Pathway to Assess Asymptomatic.
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Adenosine-stress myocardial perfusion imaging in octogenarians:
Total Artificial Heart (TAH): Survival Outcomes, Risk Factors,
. Troponin limit of detection plus cardiac risk stratification scores for the exclusion of myocardial infarction and 30-day adverse cardiac events in ED.
Lako S, Daka A, Nurka T, Dedej T, Memishaj S
Antonelli D, Koren O. Rozner E. Turgeman Y.
The Intermountain heart collaborative study
The Registry of the International Society for Heart and Lung Transplantation: Twenty- seventh official adult heart transplant report—2010  Josef Stehlik,
Ivabradine – A new option for Heart Failure Patients
Gender differences in the management of acute coronary syndrome patients: One year results from HPIAR (HP-India ACS Registry) Kunal Mahajan*, Negi PC,
Larissa Registry on CAS and CEA:
Alina M. Allen MD, Patrick S. Kamath MD, Joseph J. Larson,
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Prediction of 14-year cardiovascular outcomes by dobutamine.
Clinical outcome after SVR: Veterans Affairs
The Registry of the International Society for Heart and Lung Transplantation: Thirty-first Official Adult Heart Transplant Report—2014; Focus Theme: Retransplantation 
Troponin Elevation is Strongly Associated with Death in Dengue Patients with Cardiac Involvement Ariane Vieira Scarlatelli Macedo1, Simone Ramalho1, Henrique.
Liver only transplants in the UK Question 2: In terms of survival benefit.
Baseline characteristics of patients
Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2010
The Prevalence of and Contributed Risk Factors of Cardiovascular Diseases among People with Spinal Cord Injury: A Retrospective Study Ramzi Alajam.
The Time Dependence of Anti-thrombin Initiation in Patients with Non-ST-segment –elevation Acute Coronary Syndrome: Subgroup Analysis form the ACUITY.
Division of Cardiovascular Diseases No relevant author disclosures
Significance of Periprocedural Myocardial Infarctions in Percutaneous Coronary Interventions A New Look at an Old Topic Abhiram Prasad, MD, FRCP, FESC,
Anemia Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial Steven V. Manoukian, George.
Clonidine in Patients Having Noncardiac Surgery
HEART TRANSPLANTATION
Cholesterol Management in HIV-infected and Uninfected Patients: The Veterans Aging Cohort Study Leaf, DA, Goulet J, Goetz MB, Oursler KA, Gilbert C, Frieberg.
Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:
Ahmed A. Khattab, MD For the German Cypher Registry Investigators
Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.
Atlantic Cardiovascular Patient Outcomes Research Team
Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.
Presentation transcript:

Elevated resting heart rate in heart transplant recipients: innocent bystander or adverse prognostic indicator? UTAH (Utah Transplant Affiliated Hospitals) Cardiac Transplant Program University of Utah, Intermountain Medical Center, and Salt Lake Veterans Administration Medical Center Wachter SB, Stoddard G, Saidi A, Brunisholz K, Folsom J, Deshmukh V, Hammond L, Selzman C, Reid B, Kfoury B, Bader F, Budge D, Alharethi R, Stehlik J, Drakos S, Gilbert EM American Transplant Congress June 5, 2012

Disclosures none

Background Elevated resting heart rate is known to be a risk factor of adverse cardiovascular outcomes in the general population Studies in heart transplant patients with tachycardia also show adverse cardiovascular outcomes Effects of tachycardia on mortality in a large cohort study has not previously been presented

Hypothesis In heart transplant patients sustained tachycardia increases the risk of: All cause mortality Cardiac allograft vasculopathy

Methods Retrospective study Adult patients with OHT from 2000 – 2011 Survived post transplant at least 3 months In-patient and out-patient clinical records University of Utah Intermountain Medical Center Salt Lake Veterans Administration Medical Center

Collected Data Vital signs ECGs Left heart catheterizations Cardiac biopsies Laboratory data Baseline clinical characteristics Echocardiograms

Defining the Study Groups Average heart rate collected by physical exam during months 3 to 12 post transplant Study groups Tachycardia group Average heart rate > 100 bpm Non Tachycardia group Average heart rate ≤100 bpm

Results

Heart Rate Distribution Tachycardia HR > 100 bpm N=73 (24%) Non Tachycardia HR ≤ 100 bpm N=236 (76%) bpm

Baseline Characteristics (pre transplant) Non Tachycardia (HR ≤100) N=236 Tachycardia (HR > 100) N = 73 p-value Recipient Males80%74%0.27 Donor Males71%69%0.77 Donor CMV66%65%0.94 Recipient Age49 ± 1449 ± Donor Age24 ± 933 ± 12< * Recipient BMI27 ± 525 ± * DM9%11%0.60 HTN13%25%0.01 * CKD3%7%0.08 HLD17%26%0.07 Hypothyroid3% 0.93 CVA3%11%0.01 * Smoking44% 0.99

Heart Failure Etiology Non Tachycardia (HR ≤100) N = 236 Tachycardia (HR > 100) N= 73 CAD46%41% Idiopathic CM41%45% Congenital CM3%8% Valvular CM2%3% Post partum CM2%0% Alcoholic CM3%0% Allograft vasculopathy0%2% Hypertrophic CM1%0% Hypoplastic left heart1%0% Restrictive1%0% Sarcoid1%0% Giant cell myocarditis1%0% 46% 54% 41 % 59% p = 0.58 Ischemic Non Ischemic

Clinical Changes Post Transplant (months 3-12 post transplant) Non Tachcardic (HR ≤100) N = 236 Tachcardic HR > 100 N = 73 p-value LDL > 1007%4%0.40 TSH < 0.032%4%0.40 Hgb < 96%3%0.20 Afib by ECG0.0%1%0.40 Low EF < 50%7%3%0.08 Beta Blocker3%1%0.40 Ca 2+ Channel Blocker3%0%0.10 ACE Inhibitor8%10%0.60 Synthroid2%4%0.40

Effect of Tachycardia on All Cause Mortality Point 0 = 3 months post transplant

Effect of Tachycardia on All Cause Mortality HR ≤ 100 HR > 100 HR % CI (1.3 – 3.6), p=0.004

Effect of Tachycardia on Cardiovascular Mortality HR % CI (1.0 – 5.7), p=0.04 HR ≤ 100 HR > 100

Effect of Tachycardia on Rejection HR % CI (0.7 – 1.4), p=0.99 HR ≤ 100 HR > 100

Effect of Tachycardia on Allograft Vasculopathy HR % CI (0.4 – 1.9), p=0.68 HR ≤ 100 HR > 100

Multivariable Analysis of All Cause Mortality Variable HR (95% CI)p-value Recipient Age1.00 (0.96 – 1.04)0.93 Recipient Gender1.48 (0.50 – 4.35)0.48 Donor Age1.02 (0.98 – 1.06)0.32 Donor Gender1.08 (0.41 – 2.82)0.88 Etiology of Heart Failure0.97 (0.37 – 2.50)0.94 CMV1.20 (0.49 – 2.94)0.68 Recipient BMI0.96 (0.88 – 1.05)0.38 Heart rate > 100 bpm3.05 (1.17 – 7.94)0.02

Limitations Retrospective study design A spot measurement of heart rate does not fully reflect the circadian variability of heart rate The data suggests a significant association but does not prove causality

Conclusion Patients with tachycardia post transplant have an increased risk of all cause mortality Patients with tachycardia post transplant have an increased risk of cardiovascular death We did not find a difference in the rate of cardiac allograft vasculopathy or rejection between the two study groups

Thank you, Questions?